102 related articles for article (PubMed ID: 2151277)
1. Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer: interim analysis of an ongoing PONCAP study. Italian Prostatic Cancer Project (PONCAP).
Boccardo F; Decensi A; Guarneri D; Rubagotti A; Oneto F; Martorana G; Giuliani L; Delli Ponti U; Petracco S; Cortellini P
Eur Urol; 1990; 18 Suppl 3():48-53. PubMed ID: 2151277
[TBL] [Abstract][Full Text] [Related]
2. Total androgen blockade with Zoladex plus flutamide vs. Zoladex alone in advanced prostatic carcinoma: interim report of a multicenter, double-blind, placebo-controlled study.
Fourcade RO; Cariou G; Coloby P; Colombel P; Coulange C; Grise P; Mangin P; Soret JY; Poterre M
Eur Urol; 1990; 18 Suppl 3():45-7. PubMed ID: 2151276
[TBL] [Abstract][Full Text] [Related]
3. Zoladex plus flutamide vs. orchidectomy for advanced prostatic cancer. Danish Prostatic Cancer Group (DAPROCA).
Iversen P
Eur Urol; 1990; 18 Suppl 3():41-4. PubMed ID: 2151275
[TBL] [Abstract][Full Text] [Related]
4. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
Jurincic CD; Horlbeck R; Klippel KF
Semin Oncol; 1991 Oct; 18(5 Suppl 6):21-5. PubMed ID: 1835139
[TBL] [Abstract][Full Text] [Related]
5. Orchidectomy vs. Zoladex plus flutamide in patients with metastatic prostate cancer. The EORTC GU Group.
Denis L; Smith PH; De Moura JL; Newling DW; Bono A; Keuppens F; Robinson M; Mahler C; Sylvester R; De Pauw M
Eur Urol; 1990; 18 Suppl 3():34-40. PubMed ID: 2151274
[TBL] [Abstract][Full Text] [Related]
6. A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate.
Iversen P; Christensen MG; Friis E; Hornbøl P; Hvidt V; Iversen HG; Klarskov P; Krarup T; Lund F; Mogensen P
Cancer; 1990 Sep; 66(5 Suppl):1058-66. PubMed ID: 2144207
[TBL] [Abstract][Full Text] [Related]
7. EORTC protocol 30853: orchidectomy versus zoladex plus flutamide in the management of metastatic carcinoma of the prostate. Interim statistical analysis of the side effects of treatment.
Robinson MR; Denis L; Newling DW; Sylvester R; De Pauw M
Cancer; 1990 Sep; 66(5 Suppl):1022-4. PubMed ID: 2144204
[TBL] [Abstract][Full Text] [Related]
8. 'Zoladex' versus 'Zoladex' plus flutamide in the treatment of advanced prostate cancer. First interim analysis of an international trial. International Prostate Cancer Study Group.
Lunglmayr G
Prog Clin Biol Res; 1989; 303():145-51. PubMed ID: 2528737
[TBL] [Abstract][Full Text] [Related]
9. [Randomized study comparing zoladex versus zoladex plus flutamide in treatment of advanced cancer of the prostate].
Haefliger JM
Helv Chir Acta; 1992 Oct; 59(3):477-83. PubMed ID: 1464545
[TBL] [Abstract][Full Text] [Related]
10. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.
Boccardo F; Pace M; Rubagotti A; Guarneri D; Decensi A; Oneto F; Martorana G; Giuliani L; Selvaggi F; Battaglia M
Eur J Cancer; 1993; 29A(8):1088-93. PubMed ID: 8518017
[TBL] [Abstract][Full Text] [Related]
11. A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Tyrrell CJ; Altwein JE; Klippel F; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
J Urol; 1991 Nov; 146(5):1321-6. PubMed ID: 1834864
[TBL] [Abstract][Full Text] [Related]
12. Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Di Silverio F; Serio M; D'Eramo G; Sciarra F
Eur Urol; 1990; 18 Suppl 3():54-61. PubMed ID: 2151278
[TBL] [Abstract][Full Text] [Related]
13. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group.
Smith PH; Bono A; Calais da Silva F; Debruyne F; Denis L; Robinson P; Sylvester R; Armitage TG
Cancer; 1990 Sep; 66(5 Suppl):1009-16. PubMed ID: 2144203
[TBL] [Abstract][Full Text] [Related]
14. Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group.
Keuppens F; Denis L; Smith P; Carvalho AP; Newling D; Bond A; Sylvester R; De Pauw M; Vermeylen K; Ongena P
Cancer; 1990 Sep; 66(5 Suppl):1045-57. PubMed ID: 2144206
[TBL] [Abstract][Full Text] [Related]
15. Multicenter randomized trial comparing Zoladex with Zoladex plus flutamide in the treatment of advanced prostate cancer. Survival update. International Prostate Cancer Study Group.
Tyrrell CJ; Altwein JE; Klippel F; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP; Sotarauta M
Cancer; 1993 Dec; 72(12 Suppl):3878-9. PubMed ID: 8252508
[No Abstract] [Full Text] [Related]
16. Orchidectomy versus Zoladex plus Eulexin in patients with metastatic prostate cancer (EORTC 30853).
Denis L; Robinson M; Mahler C; Smith P; Keuppens F; De Moura JL; Bono A; Newling D; Sylvester R; De Pauw M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):951-9. PubMed ID: 2149508
[TBL] [Abstract][Full Text] [Related]
17. Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86.
Iversen P; Suciu S; Sylvester R; Christensen I; Denis L
Cancer; 1990 Sep; 66(5 Suppl):1067-73. PubMed ID: 2144208
[TBL] [Abstract][Full Text] [Related]
18. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
Lunglmayr G
Eur Urol; 1990; 18 Suppl 3():28-9. PubMed ID: 2151273
[No Abstract] [Full Text] [Related]
19. Comparison of an LH-RH analogue (Goeserelin acetate, 'Zoladex') with combined androgen blockade in advanced prostate cancer: final survival results of an international multicentre randomized-trial. International Prostate Cancer Study Group.
Tyrrell CJ; Altwein JE; Klippel F; Jurincic-Winkler C; Varenhorst E; Lunglmayr G; Boccardo F; Holdaway IM; Haefliger JM; Jordaan JP
Eur Urol; 2000 Feb; 37(2):205-11. PubMed ID: 10705200
[TBL] [Abstract][Full Text] [Related]
20. Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer.
Cooper EH; Armitage TG; Robinson MR; Newling DW; Richards BR; Smith PH; Denis L; Sylvester R
Cancer; 1990 Sep; 66(5 Suppl):1025-8. PubMed ID: 1697498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
